Inossia receives US FDA Breakthrough Device Designation
Stockholm, July 1, 2025 – Inossia AB is proud to announce today that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Inossia® Cement Softener for use with PMMA bone cement in percutaneous vertebral augmentation procedures. This is an important step in Inossia’s regulatory plan and supports the planned 510(k) submission. […]
We’re proud to welcome Anna Marsell to the board at Inossia AB!
June 10, 2025 – Anna brings more than 20 years of broad experience across the pharmaceutical, medtech, and life science sectors, with a strong track record in general management and leading global teams across strategy, commercial operations, R&D, and organisational development. She currently serves as COO at Olink Proteomics, where she leads global operations in […]
Inossia AB Successfully Closes Oversubscribed Rights Issue
Uppsala, Sweden – April 30, 2025 – Inossia AB, a pioneering company in the field of biomaterials for bone health, is pleased to announce the successful completion of its rights issue, which was oversubscribed by more than 100%. Initially targeting 5 million SEK, the rights issue closed at 10.3 million SEK, reflecting strong investor confidence […]
The road to healthier patients is driven by healthy collaborations!
April 24th, 2025 – Last week, our CEO, Malin Nilsson, traveled to Calgary with a group of interventional radiologists from the GRIBOI Annual Meeting to visit Beam Radiology — one of our key clinical trial partners. Led by Dr. Olivier Clerk, MD, FIPP, the team continues to drive innovation in the field. We’re proud to […]
Inossia Mentioned as ‘Next-wave company’ in Sweden
Feb. 10. 2025 – Inossia AB is included in Industrifonden’s latest report, recognizing Inossia as one of the next-wave companies in MedTech and diagnostics alongside other inspiring companies in Sweden. The full report can be viewed by clicking on the following link: https://industrifonden.com/news/deep-tech-funding-landscape-in-sweden/ Image credit: Industrifonden
What a year it’s been at Inossia!
December 20, 2024 – A huge thank-you to everyone who’s been part of our journey this year. We’re excited to see what challenges and opportunities next year will bring. For now, we wish you a happy holiday season and a fantastic New Year!
We’re Expanding!
We’re excited to announce that we’ve joined the Medicon Village in Lund! This move brings us closer to many innovative companies in the life sciences sector, providing a fantastic environment for collaboration and growth. Our Director of QA/RA, Anette Israelsson, is thrilled about the active networking opportunities at Medicon Village, including industry-focused groups in areas […]
Inossia’s Quality Management System ISO 13485 recertified
August 09, 2024 – In May Inossia had an external recertification audit of our Quality Management System for Medical Devices, ISO 13485:2016. RISE Research Institutes of Sweden AB carried out the audit. The ISO 13485:2016 certification was recertified without any problems. Today we got our certificate. See the certificate
Inossia at GRIBOI – Sardinia Spine in Cagliari, Italy
June 12-14, 2024 – Inossia was present at the Interdisciplinary Research Conference for Injectable Osteoarticular Biomaterials (Griboi) – Sardinia Spine in Cagliari, Italy. Our CEO Malin Nilsson was one of the keynote speakers and gave a presentation about – Benefits with soft bone cement in vertebral compression fractures: pre-clinical and clinical findings.Salim Ghandour gave a presentation […]
IVA acknowledges Inossia´s potential in treating osteoporotic fractures
February 06, 2024 – At the IVA 104th anniversary gathering, IVA’s President Tuula Teeri acknowledged the work of Professor Cecilia Persson, and especially highlighted Inossa´s huge potential in treating osteoporotic fractures. https://www.inossia.com/wp-content/uploads/2024/02/Inossia-version-1.mp4 Source:IVA
